Vertis (CEO Dong-young Noh and Seung-man Han), a precision medical technology company based on proteomics, announced on the 6th that it has recruited Dr. David Berry, a world authority on innovation and sustainable management in the field of life sciences, as a member of its Scientific Advisory Board (SAB).
Dr. David Berry holds a PhD in medicine from Harvard Medical School and a PhD in bioengineering from MIT, and holds over 200 patents in life sciences. He has participated in the founding of over 30 companies, including 7 with a corporate value of over $1 billion, and also contributed to the founding of Moderna, a company developing vaccines and therapeutics based on mRNA technology.
Dr. David Berry is a world-renowned authority on innovation and sustainable management, and currently serves as an honorary member of the Leadership Council of the United Nations Sustainable Development Solutions Network (UN SDSN). He was named 'Innovator of the Year' by MIT Technology Review published by MIT in 2007, 'Young Global Leader' by the World Economic Forum in 2014, and 'Innovators Reshaping Reality' by the U.S. State Department.
Dr. David Berry’s participation in the Vertis Scientific Advisory Board is noteworthy as it is the first time that he, an authority on innovation and sustainable management in the life sciences, is collaborating with a Korean company. Vertis is looking forward to establishing a global expansion strategy by closely working with Dr. David Berry, who has a wealth of experience and outstanding expertise as an innovation leader, inventor, and entrepreneur, and to establishing itself as a leading company in the field of proteomics-based precision medicine technology on the global stage.
Dr. David Berry said, “Vertis possesses world-class proprietary technology in the field of clinical proteomics, and is a company leading the implementation of precision medicine, such as early disease diagnosis and activation of personalized treatment, by utilizing this technology.” He added, “We will strive to spread Vertis’ proteomics-based precision medicine technology globally and contribute to creating innovation in the medical field.”
“Since its founding in 2014, Vertis has built a globally competitive technology system through continuous challenges and has achieved commercialization and technology development of proteomics technologies such as multi-protein biomarker-based blood tests,” said Seungman Han, CEO of Vertis. “We expect that the collaboration with Dr. David Berry will be a great help in Vertis’ leap forward as a precision medical technology company with global competitiveness based on the achievements of technology development accumulated over the past 10 years.”
- See more related articles
You must be logged in to post a comment.